Clinical Trial: Dose-Escalated MR-Guided Radiotherapy for Localized Prostate Cancer

U.S., June 30 -- ClinicalTrials.gov registry received information related to the study (NCT07674225) titled 'Dose-Escalated MR-Guided Radiotherapy for Localized Prostate Cancer' on May 13.

Brief Summary: DESTINATION 2 is a multi-centre randomised trial treating intermediate risk localised prostate cancer with 2 fraction Stereotactic Body Radiotherapy (SBRT). All radiotherapy will be delivered in two fractions (sessions) on an MR Linac using daily adaptation. Men will either receive uniform dose radiotherapy or de-escalated dose radiotherapy. The primary endpoint is acute GU CTCAE v5 grade 2+ toxicity. It will also look at late toxicity, patient-reported outcome measures and PSA control.

Study Start Date: March 22

Study Type: INTERVENTION...